Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases
Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109…
Palisade Bio Receives Decision To Grant European Patent Titled, ‘COMPOSITIONS FOR THE TREATMENT OF AUTODIGESTION’
https://register.epo.org/application?number=EP15767838
Moderna Announces Recipharm Site In France Now Manufacturing COVID-19 Vaccine
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO),
CNS Pharma Reports Corporate Update
Recently launched potentially pivotal study for lead program evaluating Berubicin in the treatment of adult Glioblastoma Multiforme (GBM), with patient dosing expected to commence in Q3 2021
Continued execution on
Citius Pharmaceuticals, Inc. Announces Recommendation By Independent Data Monitoring Committee To Continue Mino-Lok Phase 3 Trial As Planned
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a
Puma Biotechnology Announces FDA Approves Dose Escalation Label Update For Co.’s NERLYNX In HER2-Positive Early Stage and Metastatic Breast Cancer
Dose escalation of NERLYNX therapy demonstrated improved management and prevention of Grade 3 diarrhea
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug
Heron Therapeutics Announces U.S. Commercial Launch, Availability Of ZYNRELEF For Management Of Postoperative Pain For Up To 72 Hours
Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient